Results 61 to 70 of about 47,347 (252)

Inhaled PGE1 in neonates with hypoxemic respiratory failure: two pilot feasibility randomized clinical trials. [PDF]

, 2014
BackgroundInhaled nitric oxide (INO), a selective pulmonary vasodilator, has revolutionized the treatment of neonatal hypoxemic respiratory failure (NHRF). However, there is lack of sustained improvement in 30 to 46% of infants.
Ambalavanan, Namasivayam, Bara, Rebecca, Cotten, C Michael, Das, Abhik, Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network, Garg, Meena, Higgins, Rosemary D, Keszler, Martin, Klein, Jonathan M, Lakshminrusimha, Satyan, Malian, Monica, Nelin, Leif D, Ohls, Robin, Saha, Shampa, Sanchez, Pablo J, Shankaran, Seetha, Sood, Beena G, Van Meurs, Krisa P, Wallace, Dennis   +18 more
core   +2 more sources

Idiopathic Pulmonary Arterial Hypertension Unmasked by Pregnancy

Acute Medicine Journal, 2020
A 31-year old woman presented to the acute medical unit 9 days post-partum with shortness of breath and peripheral oedema. Initially suspected to have either a pulmonary embolism or post-partum cardiomyopathy, she proceeded to have imaging including a CT Pulmonary angiogram and echocardiogram, which were suggestive of pulmonary hypertension and severe ...
A, Maxwell, T, Holman, T, Novak
openaire   +3 more sources

Outcomes in Children With Idiopathic Pulmonary Arterial Hypertension [PDF]

Circulation, 2004
Background— Treatment for idiopathic pulmonary arterial hypertension in children includes calcium channel blockade (CCB) for acute responders with vasodilator testing and chronic epoprostenol for nonresponders. We sought to determine parameters associated with survival and treatment success.
Delphine, Yung, Allison C, Widlitz, Erika Berman, Rosenzweig, Diane, Kerstein, Greg, Maislin, Robyn J, Barst   +5 more
openaire   +2 more sources

Computational Modeling Meets 3D Bioprinting: Emerging Synergies in Cardiovascular Disease Modeling

Advanced Healthcare Materials, EarlyView.
Emerging advances in three‐dimensional bioprinting and computational modeling are reshaping cardiovascular (CV) research by enabling more realistic, patient‐specific tissue platforms. This review surveys cutting‐edge approaches that merge biomimetic CV constructs with computational simulations to overcome the limitations of traditional models, improve ...
Tanmay Mukherjee, Mehdi Salar Amoli, Sarah Rezapourdamanab, Lama Rita El Shammas, Martin L. Tomov, Emilio A. Mendiola, Vahid Serpooshan, Reza Avazmohammadi   +7 more
wiley   +1 more source

Hypoxemia during sleep and overnight rostral fluid shift in pulmonary arterial hypertension: a pilot study

Pulmonary Circulation, 2021
Sleep-related breathing disorders, including sleep apnea and hypoxemia during sleep, are common in pulmonary arterial hypertension, but the underlying mechanisms remain unknown.
Etienne-Marie Jutant, David Montani, Caroline Sattler, Sven Günther, Olivier Sitbon, Gilles Garcia, Isabelle Arnulf, Marc Humbert, Thomas Similowski, Stefania Redolfi   +9 more
doaj   +1 more source

Response to pulmonary arterial hypertension drug therapies in patients with pulmonary arterial hypertension and cardiovascular risk factors. [PDF]

, 2014
The age at diagnosis of pulmonary arterial hypertension (PAH) and the prevalence of cardiovascular (CV) risk factors are increasing. We sought to determine whether the response to drug therapy was influenced by CV risk factors in PAH patients. We studied
Charalampopoulos, A, Connolly, SB, Davies, RJ, Gibbs, JS, Gin-Sing, W, Grapsa, J, Howard, LS, Nihoyannopoulos, P, Tzoulaki, I, Wilkins, MR   +9 more
core   +1 more source

CXCL13 in idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension [PDF]

Respiratory Research, 2016
Chemokine CXC ligand 13 (CXCL13) has been implicated in perivascular inflammation and pulmonary vascular remodeling in patients with idiopathic pulmonary artery hypertension (IPAH). We wondered whether CXCL13 may also play a role in chronic thromboembolic pulmonary hypertension (CTEPH) and whether serum levels of CXCL13 might serve as biomarkers in ...
Olsson, Karen M., Olle, Sandra, Fuge, Jan, Welte, Tobias, Hoeper, Marius M., Lerch, Christian, Maegel, Lavinia, Haller, Hermann, Jonigk, Danny, Schiffer, Lena   +9 more
openaire   +2 more sources

Decoding the Cardiac Immune Microenvironment and Fibroblast Crosstalk in Radiotherapy Combined with Immunotherapy‐Induced Cardiac Fibrosis Based on Single‐Cell Transcriptomic Analysis

Advanced Science, EarlyView.
This study highlights that radioimmunotherapy drives crosstalk between fibroblasts and immune cells (especially macrophages) in the cardiac microenvironment, with IL‐6 as the key mediator, and tocilizumab alleviates cardiac fibrosis by targeting this interplay.
Yuxi Luo, Ying Yu, Zhimin Zeng, Yanxin Chen, Yali Yi, Zhiqin Lu, Fujuan Zeng, Peng Xu, Daya Luo, Leifeng Chen, Anwen Liu   +10 more
wiley   +1 more source

Endothelial cells and pulmonary arterial hypertension: apoptosis, proliferation, interaction and transdifferentiation

Respiratory Research, 2009
Severe pulmonary arterial hypertension, whether idiopathic or secondary, is characterized by structural alterations of microscopically small pulmonary arterioles.
Sakao Seiichiro, Tatsumi Koichiro, Voelkel Norbert F   +2 more
doaj   +1 more source

Endothelial to mesenchymal transition (EndoMT) in the pathogenesis of Systemic Sclerosis-associated pulmonary fibrosis and pulmonary arterial hypertension. Myth or reality? [PDF]

, 2016
Systemic Sclerosis (SSc) is a systemic autoimmune disease characterized by progressive fibrosis of skin and multiple internal organs and severe functional and structural microvascular alterations.
Jimenez, Sergio A., Piera-Velazquez, Sonsoles   +1 more
core   +2 more sources